Continuously-Infused Human C-Reactive Protein Is Neither Proatherosclerotic Nor Proinflammatory in Apolipoprotein E–Deficient Mice

Restricted accessOtherFirst published online June, 2009

Continuously-Infused Human C-Reactive Protein Is Neither Proatherosclerotic Nor Proinflammatory in Apolipoprotein E–Deficient Mice

, , [...], and

Volume 234, Issue 6https://doi.org/10.3181/0812-RM-347

Abstract

Studies of human native C-reactive protein (nCRP) in mice have shown effects ranging from proatherogenic, to antiatherogenic, to no effect. It is likely that these disparities are related to (a) the use, in some studies, of contaminated nCRP, or to (b) variation in CRP levels associated with either its episodic administration or the use of CRP-transgenic mice. In our study, 12-week-old male apolipoprotein E–deficient (apoE ^−/−) mice, maintained on a Western diet, received azide- and endotoxin-free nCRP (n = 23) or placebo (n = 23) continuously via osmotic pumps (20.4 μg/day) for 4 weeks. CRP-treated and control mice developed similar atherosclerotic lesions in whole aortas (nCRP: 10.4 ± 4.7% vs. controls: 11.7 ± 4.4%, P = 0.76) and aortic roots (nCRP: 65.0 ± 7.8% vs. controls: 64.7 ± 9.7%, P = 0.94). No differences were observed in macrophage or T-lymphocyte infiltrates and there was no meaningful change in VCAM-1 or IL-6 expression, in the levels of soluble VCAM-1, or in circulating proinflammatory (IL-1β, IL-6, IL-12p40, IL-12p70, TNF-α, and INF-γ), or anti-inflammatory (IL-4 and IL-10) cytokines. We conclude that continuous infusion of uncontaminated nCRP in apoE ^−/− mice is not associated with increased atherosclerosis, does not alter systemic or local inflammation, and does not affect endothelial activation. These observations suggest that alternative approaches to study CRP (perhaps using different pentraxins in the mouse model or using a rabbit model instead of a mouse model) are needed to evaluate the effects of pentraxins on atherosclerosis.

Get full access to this article

View all access options for this article.

References

1.

Steg PG, Bhatt DL, Wilson PWF, D’Agostino SR, Ohman EM, Röther J, Liau C-S, Hirsch AT, Mas J-L, Ikeda Y, Pencina MJ, Goto S, for the REACH Investigators. One-year cardiovascular event rates in out-patients with atherothrombosis. JAMA 297:1197–1206, 2007.

2.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695, 2005.

3.

Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 Suppl (6A):9S–16S, 2004.

4.

Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 111:1805–1812, 2003.

5.

Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117:499–507, 2004.

6.

Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2:29–36, 2005.

7.

Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360: 1462–1467, 2002.

8.

Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165–2168, 2000.

9.

Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 173:35–43, 2001.

10.

Paul A, Ko KWS, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E–deficient mice. Circulation 109:647–655, 2004.

11.

Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA, Galle J. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E–knockout mice. Circulation 112:1016–1023, 2005.

12.

Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E–deficient mice. Proc Natl Acad Sci U S A 102:8309–8314, 2005.

13.

Trion A, de Maat MPM, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HMG, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 25:1635–1640, 2005.

14.

Torzewski M, Reifenberg K, Cheng F, Wiese E, Kupper I, Crain J, Lackner KJ, Bhakdi S. No effect of C-reactive protein on early atherosclerosis in LDLR(−/−)/human C-reactive protein transgenic mice. Thromb Haemost 99:196–201, 2008.

15.

Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB. Transgenic human CRP is not proatherogenic, proatherothrombotic or proinflammatory in apoE ^−/− mice. Atherosclerosis 196:248–255, 2008.

16.

Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci U S A 104:13768–13773, 2007.

17.

Szalai AJ, McCrory MA. Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunol Res 26:279–287, 2002.

18.

Reifenberg K, Lehr H-A, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol 25:1641–1646, 2005.

19.

Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusinol AE, Agrawal A. C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 180:4316–4322, 2008.

20.

Chang M-K, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99:13043–13048, 2002.

21.

Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118:75–83, 2008.

22.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511, 2003.

23.

Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 201:318–325, 2008.

24.

Taylor KE, Giddings JC, van den Berg CW. C-reactive protein–induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25:1225–1230, 2005.

25.

Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, Caplice NM. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 97:135–143, 2005.

26.

Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97:e97–e103, 2005.

27.

Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 48: 509–512, 2007.

28.

Szalai AJ, Nataf S, Hu X-Z, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168:5792–5797, 2002.

29.

Jiang S, Xia D, Samols D. Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis. Scand J Rheumatol 35:351–355, 2006.

30.

Rodriguez W, Mold C, Kataranovski M, Hutt JA, Marnell LL, Verbeek JS, Du Clos TW. C-reactive protein–mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcg receptors. J Immunol 178:530–538, 2007.